Krönke et al. (2015) recently used quantitative proteomics and mass spectrometry analysis to examine the mode of action behind lenalidomide’s impressive efficacy in treating del(5q) myelodysplastic syndrome (MDS).1 In conjunction with molecular techniques, they demonstrated that the immunomodulatory (IMiD) agent targets casein kinase 1A1 (CK1α) for proteasomal degradation via ubiquitination. The del(5q) MDS patients show deletion Read the rest of this article
The post Proteomic Evaluation of Lenalidomide Efficacy in del(5q) Myelodysplastic Syndrome appeared first on Accelerating Science.
from Accelerating Science » Amanda Maxwell http://ift.tt/1IebBEL